GlassScriptPhysician profile
Peyman Pahlavan
NPI 1063450757
$12,590.60
in general payments reported to CMS, 2019-2025
39 companies · $1,891 in 2025
The $1,891 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $698 · 2021: $1,491 · 2022: $2,057 · 2023: $2,928 · 2024: $2,587 · 2025: $1,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,374 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,373.97 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,523.76 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Novo Nordisk INC | $1,786.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,530.22 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $1,348.28 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $742.64 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $712.58 | 2021-2025 | |
| Medtronic, INC. | $535.28 | 2023-2025 | Sonicision, Signia |
| Glaxosmithkline, LLC. | $523.13 | 2019-2025 | Pediarix, Bexsero, Arexvy |
| Mylan Specialty L.P. | $507.75 | 2021-2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $380.38 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $329.93 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Baxter Healthcare | $220.72 | 2023-2024 | Peri-Strips Dry |
| Pfizer INC. | $219.46 | 2019-2025 | |
| Abbott Laboratories | $159.08 | 2022-2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $157.69 | 2025 | Spyglass Discover |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peyman Pahlavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.